Vaxfectin™-Formulated Influenza DNA Vaccines Encoding NP and M2 Viral Proteins Protect Mice against Lethal Viral Challenge

Gretchen S. Jimenez, Rodrick Planchon, Qun Wei, Denis Rusalov, Andrew Geall, Joel Enas, Peggy Lalor, Vicky Leamy, Ruth Vahle, Catherine J. Luke, Alain Rolland, David C. Kaslow and Larry R. Smith

volume 3 | issue 5

september/october 2007
Pages: 157 - 164

This is an open-access article

Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.

Next generation influenza vaccines containing conserved antigens may enhance immunity against seasonal or pandemic influenza virus strains. Using a plasmid DNA (pDNA)-based vaccine approach, we systematically tested combinations of NP, M1, and M2 antigens derived from consensus sequences for protection against lethal influenza challenge and compared formulations for adjuvanting low pDNA vaccine doses. The highest level of protection at the lowest pDNA doses was provided by Vaxfectin™-formulated NP + M2. Vaxfectin™ adjuvanticity was confirmed with a low dose of HA pDNA. These promising proof-of-concept data support the clinical development of Vaxfectin™-formulated pDNA encoding NP + M2 consensus proteins.